Cantargia is developing antibodies against IL1RAP. Interim data from CANFOUR (Phase Ib/IIa) in NSCLC and PDAC suggest that nadunolimab could be synergistic with chemotherapy; the latest update (ESMO 2024) showed encouraging survival data in 40 NSCLC patients. Supportive clinical/biomarker data for PDAC have also been reported and Cantargia is preparing for a Phase IIb trial in PDAC. It shared positive data from TRIFOUR (Phase Ib portion), assessing nadunolimab in triple-negative breast cancer; the Phase II portion is ongoing with initial results expected in H125. A new Phase Ib/IIa clinical trial for nadunolimab in leukaemia is expected to start in Q424. A second programme, CAN10 (Phase I), is ongoing in autoimmune diseases (MAD part due to start in Q324), and supportive preclinical data have recently been presented in fibrotic lung diseases and dermatology. At end-Q224, Cantargia had c SEK105m in cash and short-term investments.